Evolus Inc logo

Evolus Inc

$ 10.21 -0.4 (-3.77%) 11:08 PM EST
P/E:
At Loss
P/B:
11.55
Market Cap:
$ 572.73M
Enterprise V:
$ 585.27M
Volume:
385.32K
Avg Vol (2M):
562.76K
Also Trade In:
Volume:
385.32K
Market Cap $:
572.73M
PE Ratio:
At Loss
Avg Vol (2-Month):
562.76K
Enterprise Value $:
585.27M
PB Ratio:
11.55
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Evolus Inc
NAICS : 325411 SIC : 2833
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Description
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company generates product revenue from the sale of Jeuveau in the US.
Name Current Vs Industry Vs History
Cash-To-Debt 1.13
Equity-to-Asset 0.22
Debt-to-Equity 1.59
Debt-to-EBITDA -1.07
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.08
Distress
Grey
Safe
Beneish M-Score -1.16
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 55.69
9-Day RSI 47.87
14-Day RSI 44.92
6-1 Month Momentum % 49.26
12-1 Month Momentum % 24.1

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.6
Quick Ratio 2.36
Cash Ratio 1.64
Days Inventory 32.15
Days Sales Outstanding 42.8
Days Payable 51.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -26.8

Financials (Next Earnings Date:2022-11-02 Est.)

EOLS's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:EOLS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 132.405
EPS (TTM) ($) -1.41
Beta 1.11
Volatility % 61.78
14-Day RSI 44.92
14-Day ATR ($) 0.717546
20-Day SMA ($) 10.5125
12-1 Month Momentum % 24.1
52-Week Range ($) 5.061 - 14.34
Shares Outstanding (Mil) 56.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Evolus Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More